180 related articles for article (PubMed ID: 27029112)
1. [ROLE OF VARIOUS ANTIGENIC PREPARATIONS OF FRANCISELLA TULARENSIS IN FORMATION OF ALLERGY REACTION IN HUMANS AND ANIMALS].
Onoprienko NN; Aronova NV; Pavlovich NV
Zh Mikrobiol Epidemiol Immunobiol; 2016; (1):22-9. PubMed ID: 27029112
[TBL] [Abstract][Full Text] [Related]
2. Immunological markers that correlate with protection immunity against tularemia infection.
Firstova VV; Mokrievich AN; Pavlov VM; Gorbatov AA; Kombarova TI; Biketov SF; Dyatlov IA
Adv Exp Med Biol; 2014; 808():15-23. PubMed ID: 24595607
[TBL] [Abstract][Full Text] [Related]
3. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
Baron SD; Singh R; Metzger DW
Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
[TBL] [Abstract][Full Text] [Related]
4. [The protective properties of the outer membranes of Francisella tularensis in an experimental infection in guinea pigs].
Khlebnikov VS; Golovlev IR; Chugunov AM; Zhemchugov VE; Averin SF; Afanas'ev SS; Pshirkov SIu; Konovalov SI; Stepanov AV
Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):84-8. PubMed ID: 8184621
[TBL] [Abstract][Full Text] [Related]
5. Virulence determinants and protective antigens of Francisella tularensis.
Sjöstedt A
Curr Opin Microbiol; 2003 Feb; 6(1):66-71. PubMed ID: 12615222
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of immunobiological activity of Francisella tularensis C-complex preparations as promising component of subunit vaccines].
Volokh OA; Shepelev IA; Firsova VV; Khramkova EM; Avdeeva NG; Samokhvalova IuI; Eremin SA; Diatlov IA; Zhemchugov VE
Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):16-21. PubMed ID: 17672125
[TBL] [Abstract][Full Text] [Related]
7. [Phase variations of Francisella tularensis lipopolysaccharide in human infection and immunization].
Aronova NV; Pavlovich NV
Zh Mikrobiol Epidemiol Immunobiol; 2005; (4):8-12. PubMed ID: 16146218
[TBL] [Abstract][Full Text] [Related]
8. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.
McCormick AA; Shakeel A; Yi C; Kaur H; Mansour AM; Bakshi CS
PLoS One; 2018; 13(4):e0194614. PubMed ID: 29684046
[TBL] [Abstract][Full Text] [Related]
9. [Comparative analysis of the immune response of a rabbit to antigens to live and killed Francisella species bacteria].
Aronova NV; Pavlovich NV
Mol Gen Mikrobiol Virusol; 2001; (2):26-30. PubMed ID: 11449797
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
[TBL] [Abstract][Full Text] [Related]
11. Modulation of delayed-type hypersensitivity and cellular immunity to microbial vaccines: effects of cyclophosphamide on the immune response to tularemia vaccine.
Ascher MS; Parker D; Turk JL
Infect Immun; 1977 Nov; 18(2):318-23. PubMed ID: 924675
[TBL] [Abstract][Full Text] [Related]
12. Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen.
Conlan JW; Vinogradov E; Monteiro MA; Perry MB
Microb Pathog; 2003 Jan; 34(1):39-45. PubMed ID: 12620383
[TBL] [Abstract][Full Text] [Related]
13. Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.
Tärnvik A; Eriksson M; Sandström G; Sjöstedt A
Immunology; 1992 Jul; 76(3):349-54. PubMed ID: 1526645
[No Abstract] [Full Text] [Related]
14. [Comparative analysis of parameters of humoral and cell specific immunity in individuals immunized with a live tularemia vaccine].
Aronova NV; Onoprienko NN; Tsimbalistova MV; Pavlovich NV
Zh Mikrobiol Epidemiol Immunobiol; 2014; (5):32-7. PubMed ID: 25536768
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
[TBL] [Abstract][Full Text] [Related]
16. Membrane proteins of Francisella tularensis LVS differ in ability to induce proliferation of lymphocytes from tularemia-vaccinated individuals.
Surcel HM; Sarvas M; Helander IM; Herva E
Microb Pathog; 1989 Dec; 7(6):411-9. PubMed ID: 2622330
[TBL] [Abstract][Full Text] [Related]
17. Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism.
Tärnvik A; Ericsson M; Golovliov I; Sandström G; Sjöstedt A
FEMS Immunol Med Microbiol; 1996 Mar; 13(3):221-5. PubMed ID: 8861033
[TBL] [Abstract][Full Text] [Related]
18. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine.
McMurry JA; Gregory SH; Moise L; Rivera D; Buus S; De Groot AS
Vaccine; 2007 Apr; 25(16):3179-91. PubMed ID: 17291638
[TBL] [Abstract][Full Text] [Related]
19. Expansion of Vgamma9 Vdelta2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination.
Poquet Y; Kroca M; Halary F; Stenmark S; Peyrat MA; Bonneville M; Fournié JJ; Sjöstedt A
Infect Immun; 1998 May; 66(5):2107-14. PubMed ID: 9573096
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.
Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J
Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
